Dapivirine is an experimental anti-HIV drug which belongs to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of drugs. It is also called TMC120. Other drugs from this class include efavirenz (Sustiva) and nevirapine (Viramune).

Dapivirine was being developed by Tibotec/Virco as a second generation NNRTI to work against HIV which is resistant to the currently available NNRTIs. However, development of dapivirine as a treatment for HIV has been abandoned due to its poor absorption when taken orally.

In March 2004, the International Partnership for Microbicides made an agreement with Tibotec/Virco to develop dapivirine as a microbicide to prevent HIV infection, both in a gel and in a slow-release vaginal ring. In animal models, it is highly protective against infection, and phase I clinical trials in women have shown no evidence of adverse effects.